Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IK 175

Next Previous
Drug Profile

IK 175

Alternative Names: IK-175; KYN-175

Latest Information Update: 01 Aug 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ikena Oncology
  • Developer Bristol-Myers Squibb; ImageneBio
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aryl hydrocarbon receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Solid tumours; Urogenital cancer

Most Recent Events

  • 28 Jul 2025 Ikena Oncology has merged with Inmagene to form ImageneBio
  • 31 May 2024 Adverse events data from phase I trial in Urogenital cancer and Solid tumours presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 13 May 2024 IK 175 is available for licensing as of 13 May 2024 https://www.sec.gov/ix?doc=/Archives/edgar/data/1835579/000095017024029651/ikna-20231231.htm

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top